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The World Health Organization now recommends semiannual mass drug administration
(MDA) of albendazole with integrated vector management as an option for eliminating lym-
phatic filariasis (LF) in areas of loiasis-endemic countries where it may not be safe to use
diethylcarbamazine or ivermectin in MDA programs. However, the published evidence base
to support this policy is thin, and uptake by national programs has been slow.
Methodology/Principal findings
We conducted a community trial to assess the impact of semiannual MDA on lymphatic fila-
riasis and soil-transmitted helminth infections (STH) in two villages in the Bandundu prov-
ince of the Democratic Republic of the Congo with moderately high prevalences for LF and
hookworm infections. MDA with albendazole was provided every six months from June
2014 to December 2017 with treatment coverages of the eligible population (all� 2 year of
age) that ranged between 56% and 88%. No adverse effects were reported during the trial.
Evaluation at 48 months, (i.e. 6 months after the 8th round of MDA), showed that W. ban-
crofti microfilaremia (Mf) prevalence in the study communities had decreased between 2014
to 2018 from 12% to 0.9% (p<0.001). The prevalence of W. bancrofti antigenemia was also
significantly reduced from 31.6% to 8.5% (p<0.001). MDA with albendazole also reduced
hookworm, Ascaris lumbricoides and Trichuris trichiura infection prevalences in the commu-
nity from 58.6% to 21.2% (p<0.001), from 14.0% to 1.6% and 4.1% to 2.9%, respectively.
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Hookworm and Ascaris infection intensities were reduced by 93% (p = 0.02) and 57% (p =
0.03), respectively. In contrast, Trichuris infection intensity was not significantly reduced by
MDA (p = 0.61) over this time period.
Conclusion/Significance
These results provide strong evidence that semiannual MDA with albendazole alone is a
safe and effective strategy for LF elimination in Central Africa. Community MDA also had a
major impact on STH infections.
Author summary
In low-income rural settings of Africa, populations are commonly affected by multiple
parasitic diseases. Some of these diseases have been targeted for elimination through
dedicated national or international programs. In 2012, the World Health Organization
(WHO) defined a specific strategy to eliminate lymphatic filariasis, the disease respon-
sible for elephantiasis, in central Africa. This strategy consists in treating the whole
population living in endemic areas every six months with a single donated drug—alben-
dazole. Together with the use of the night bed nets distributed as part of malaria pro-
grams, it was expected that this strategy could interrupt the transmission and eliminate
lymphatic filariasis locally within period of 4 to 7 years. Here, we evaluated this strategy
in two endemic communities near Bandundu in the Democratic Republic of the Congo.
We also assessed the impact of the semiannual community treatments on three species
of gastrointestinal parasitic worms. Our results suggest that semiannual MDA with
albendazole is effective for LF elimination in Central Africa, but they also indicate that
drug-based only intervention is not enough to eliminate gastrointestinal worm infec-
tions in areas with high transmission.
Introduction
Lymphatic filariasis (LF) in Africa is caused by Wuchereria bancrofti and is transmitted mainly
by Anopheles or Culex mosquitoes. In 2000, the World Health Organization (WHO) launched
an elimination program for LF that was based on an innovative rapid mapping procedure to
identify endemic areas, and annual mass drug administration (MDA) of albendazole (ALB,
400 mg) plus ivermectin (150–200 μg/kg) in countries where onchocerciasis is coendemic with
LF, and with ALB plus diethylcarbamazine (DEC) in countries with no onchocerciasis. More
than 7 billion treatments were delivered to populations in need between 2000 and 2017, and
this has had a substantial impact on infection prevalence and intensity of transmission [1].
However, the presence of Loa loa in Central Africa prevents the widespread use of ivermectin
for LF elimination in areas that are not already receiving ivermectin for onchocerciasis control,
because ivermectin sometimes causes serious adverse events that can include coma and death
in individuals with high L. loa microfilaremia [2]. This situation represents a major challenge
for LF elimination in Africa.
WHO proposed a provisional strategy for controlling LF in areas with coendemic loiasis
but where onchocerciasis is absent in 2012. This consists of MDA using ALB (preferably with
semiannual delivery) together with integrated vector management [3]. It has been estimated
that 1.4 million people live in areas potentially targetable with this treatment scheme. [4] So
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far, this strategy has been supported by results from a single published study that was con-
ducted in an area in the Republic of the Congo where baseline circulating filarial antigenemia
(CFA) and microfilaremia (Mf) prevalences were moderate (17.3% and 5.3%, respectively) [5].
In June 2014, we started a parallel trial in an area of the Democratic Republic of the Congo
with significantly higher baseline infection prevalences. This paper reports the impact of eight
rounds of MDA with ALB on LF and on STH in this high endemicity setting.
Methods
Study design
The objective of this study was to assess the impact of semiannual community treatments with
ALB on LF and STH over a 4-year period. The study was conducted in Mbunkimi (3˚31041@S,
17˚37044@E) and Misay (3˚30044@S, 17˚37029@E), two contiguous villages located in a savanna
area of the Kwilu province, in the Democratic Republic of the Congo. Due to their proximity
and similarity, the two villages were considered to be one community for this study. An
exhaustive census of the population was conducted in April 2014, approximately one month
before the start of the trial. The census was updated prior to each round of MDA to enable pre-
cise calculations of treatment coverage (see below). Baseline and post-treatment parasitological
assessments for LF and STH were conducted between mid-June and mid-July for the years
2014, 2015, 2016, 2017 and 2018. MDA using ALB was conducted every year just after the
parasitological examinations, and also in late December 2014, 2015, 2016 and 2017. Therefore,
each parasitological assessment occurred 6 months after the previous MDA. Annual parasito-
logical assessments were performed for those� 5 years of age. During each round of MDA,
ALB was also offered to all children aged 2–4 years of age, but they were not targeted for para-
sitological assessment.
Detection of W. bancrofti infections
W. bancrofti infections were detected by antigen testing with mf testing reserved for those with
positive antigen tests. CFA was detected with the Filariasis Test Strip (FTS) (Alere-Scarbor-
ough, Scarborough, ME) according to the manufacturer’s instructions. The results were scored
semi-quantitatively as previously described [6]. All individuals with a positive FTS (score� 1)
were invited to return for blood sampling between 10:00 PM and 1:00 AM for assessment of
W. bancrofti mf. Fingers were cleaned with an alcohol wipe and pricked with a 1.5 X 2.0 mm
BD Microtainer contact activated lancet (Becton Dickenson, Franklin Lakes, NJ). Blood was
collected with a capillary tube, and two blood smears (volume 70 μL each) were prepared for
each subject. On the next day, the blood smears were dehemoglobinized, stained with Giemsa,
and examined by two experienced microscopists. Each microscopist read one of the two slides
from each subject. Differences of>10% in Mf counts were resolved by re-examination of both
slides. The Mf count for individual subjects was defined as the arithmetic mean of the counts
from the two slides and reported as mf per milliliter of blood (mf/mL).
Detection of STH infections
Every day, about 10 households listed in the census register were visited, and all occupants
aged 5 years or older were asked to report for testing and treatment on the next day. They
were also given a 50 mL plastic stool container and asked to collect a sample of their stool the
following morning. The stools specimens were collected every day at around 9 AM, stored in
cooling boxes with ice packs and shipped within 6 hours to the laboratory where they were
placed in a refrigerator at 6˚C. From each sample, two thick smears were prepared within 24 h
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of collection according to the modified Kato-Katz method [7]. Slides were examined by
microscopy at a 40x magnification within 1 hour after preparation, and results were reported
as eggs per gram of stool (epg).
Drug distribution, treatment coverage and bednet usage
Individuals who had a negative CFA result were immediately treated with ALB (400 mg)
which was taken on the spot under the direct observation of investigators. Those with positive
CFA results received the drug just after collection of night blood for mf testing. Finally, all
inhabitants who had not participated in the parasitological survey or who missed the night
blood testing (due to absence or refusal) were later visited at home and offered ALB treatment.
All drugs were distributed under the supervision of a local healthcare worker who was also in
charge of the population census. For treatment of young children, ALB tablets were crushed
with a spoon and mixed with water. Although WHO considers that pregnant women can be
treated with ALB during the second or third trimester, we decided to exclude all pregnant
women from MDA. ALB was offered to them by the local healthcare worker after they gave
birth. The treatment coverage was calculated as the number of individuals who received the
drug divided by the population aged� 2 years old as recorded in the census prior to the MDA.
For each individual, we computed the total number of ALB doses received during the study
according to the information reported in treatment books. Bed net usage was assessed with the
question “Did you sleep under a bed net last night?”
Statistical analysis
The cumulative number of treatments received by the participants who were present in June
2018 was analyzed as a function of age and gender using an analysis of variance followed by a
Tukey HSD post hoc test. Infection prevalence in the population between the baseline exami-
nation round and year 4 were compared independently for each parasite with the Chi-squared
test. Infection intensities for each W. bancrofti microfilaremia (mf/mL) and for STH infection
(eggs per gram, epg) were compared using the Mann-Whitney test. A longitudinal analysis of
prevalence and infection intensities was conducted in a subgroup of individuals who were
examined both at baseline and at year 4 using McNemar and Wilcoxon signed ranks tests,
respectively. Mean infection intensity measures for W. bancrofti (mf/mL) and STH (epg), are
reported as geometric means of positive counts (GM) or arithmetic means (AM).
The prevalence of W. bancrofti microfilaria carriers in the community was calculated
assuming that persons with negative CFA results had mf counts of zero, and the community
microfilarial load was calculated as the Williams geometric mean (i.e. the geometric mean of
(Mf counts+1) minus 1). For STH infections, we considered classes of infection intensity in
accordance with the WHO guidelines [8].
Ethical clearance
This study was approved by the Health Ethics Committee (Comité National d’Ethique de la
Santé, CNES) of the Democratic Republic of the Congo and conducted with personnel of the
Ministry of Public Health of the country. The purpose of the study was verbally presented dur-
ing meetings with village leaders and then to all study participants in both French and Lingala
(national official language). A document written in French and in Lingala detailing the study
purpose and activities was also given to each individual. Adult participants signed an informed
consent form. Participants younger than 18 years of age were enrolled only if they expressed
verbal assent to participate in the study and if at least one parent signed a parental consent
form.
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Results
Study participants and treatment coverage
In June 2014, Mbunkimi and Misay had a total population of 1290 inhabitants, among which
1033 were� 5 years of age. The population size, number of participants who underwent CFA
testing, night blood smears sampling and who provided stools are presented in Table 1. There
were no exclusion criteria regarding CFA testing. Therefore all consenting residents of the
study communities ages > 5 years were tested for CFA regardless of whether they were eligible
for treatment.
The treatment coverage ranged between 56% and 87.8% during the 5-year period (Table 1).
No adverse events were reported after the 8308 ALB treatments distributed throughout the
study. Among the 531 individuals who were examined in June 2018, the median number of ALB
doses received between June 2014 and December 2017 was 7 (Interquartile range IQR: 5–8). The
total number of albendazole doses was not dependent on gender (p-value = 0.4033) but varied
across age-groups (p-value = 0.0021), with the lowest value recorded in the 20–29 year-old group
(mean = 3.8) and the highest values in the 5–9 (mean = 5.35) and 10–14 (mean = 5.55) groups.
Impact of eight semiannual community ALB treatments on lymphatic
filariasis in the community
The CFA prevalence in the community decreased from 31.6% (95% confidence interval, CI:
28.5–34.9) in 2014 to 8.5% (95% CI: 6.4–11.2) in 2018 (p-value<0.001, see Fig 1 for interim
CFA rates). The most important drop in CFA prevalence was observed in the 40–49 year-old
age group: CFA dropped from 58.1% (95% CI: 46.4–68.9) in 2014 to 25% (95% CI: 13.2–42.1)
in 2018 (Fig 2). Of note, in 2018, there were no CFA carriers in the youngest age-group (Fig 2).
In 2018, contrary to observations from the previous years, most positive FTS had scores of 1
(low intensity) and no FTS had scores of 3 (high intensity) (Fig 1). Assuming that all individuals
Table 1. CFA, circulating filarial antigenemia by the Filariasis Test Strip (FTS).
June 2014 Dec. 2014 June 2015 Dec. 2015 June 2016 Dec. 2016 June 2017 Dec. 2017 June 2018
Total Population 1266 1276 1316 1336 1335 1321 1324 1296 1278
Pop� 2 years 1177 1197 1194 1241 1233 1260 1299 1273 1275
Treated (% of Pop� 2 years) 924 (78.5) 902 (75.4) 846 (70.9) 1046 (84.3) 878 (71.2) 1106 (87.8) 815 (62.7) 1077 (84.6) 714 (56.0)
No. participants for LF assessment 820 - 795 - 766 - 701 - 531
Age, years� 20 (10–35) - 18 (10–33) - 18 (10–34) - 16 (9–33) - 19 (11–35)
Sex-ratio (M/F)� 0.88 - 0.96 - 0.82 - 1.12 - 1.29
No. CFA+(% of examined) 259 (31.6) - 228 (28.7) - 158 (20.6) - 107 (15.3) - 45 (8.5)
No. Night blood smears 249 - 202 - 138 - 95 - 43
No. Night blood smears with mf (%)1 97 (39%) - 62 (30.7%) - 29 (21%) - 13 (13.7%) - 5 (11.6%)
No. stool samples 413 - 214 - 308 - 251 - 184
Age, years§ 19 (10–36) - 16.5 (8–39) - 15 (8–35) - 10 (8–15) - 10 (8–12)
Sex ratio§ 0.75 - 1.00 - 0.96 - 1.21 - 1.79
Bednet usage (verbal report)� 61.1% - 50.6% - 98.3% - 63.6% - 46.1%
Mf, microfilaremia
1 percentage of blood smears with microfilariae in individuals with positive CFA test results
Data are n, n (%), or median (Inter Quartile Range), unless otherwise specified
� In patients tested with FTS.
§In patients tested for soil-transmitted helminths
https://doi.org/10.1371/journal.pntd.0008322.t001
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with a negative CFA test do not harbor microfilariae, the estimated Mf prevalence in the com-
munity decreased from 12% (95% CI: 9.9–14.4) in 2014 to 0.9% (95% CI: 0.4–2.3) in 2018 (p-
value<0.001). Mf density calculated as the geometric mean of positive counts decreased from
171 mf/mL in 2014 to 70.6 mf/mL in 2018 (p-value = 0.0004, Fig 1) and the community Mf
load decreased from 0.9 mf/mL in 2014 to 0.06 mf/mL in 2018.
Impact of eight semiannual community ALB treatments on lymphatic
filariasis in a sub-group of individuals examined both in 2014 and 2018
Effect of ALB on W. bancrofti was assessed in a subset of 320 individual who were tested in 2014
and in 2018 to assess impact of annual MDA on LF infection intensity. Ninety-six (30%) had
positive CFA tests at baseline; 59 of 96 persons in this group (61.5%) had negative antigen test
results in 2018. 35 (36.5%) with persistent filarial antigenemia had lower intensity scores. One
(1%) participant had an increased score (from 1 to 2) and one (1%) had the same score of 1 in
2014 and 2018 (Table 2). Of note, none of 224 CFA negative individuals at baseline had positive
CFA tests in 2018. Mf prevalence and geometric mean of positive mf counts in the group of 320
individuals with a 4-year follow-up decreased from 11.6% to 1.3% (p-value<0.0001) and from
291.2 mf/mL (in 37 positive individuals) to 125.1 mf/mL (in 4 positive individuals) (p-value =
0.0003), respectively.
Impact of eight semiannual community ALB treatments on soil
transmitted helminth infections
The prevalence of hookworm infection in the community decreased progressively from 58.6%
in 2014 to 21.2% in 2018 (p-value<0.001, Table 3). The arithmetic mean egg count for
Fig 1. CFA and microfilaremia rates during the 4-year period.
https://doi.org/10.1371/journal.pntd.0008322.g001
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hookworm decreased from 456 epg in 2014 to 31 epg in 2018 (p-value<0.0001). In 2018,
all remaining infected individuals were in the lowest WHO category for infection intensity
(< 2000 epg) (Fig 3a). The prevalence of A. lumbricoides infection in the community decreased
from 14% in 2014 to 1.6% in 2018 (p-value<0.0001). The arithmetic mean of A. lumbricoides
egg counts decreased from 578 epg in 2014 to 173 epg in 2015 to 248 epg in 2018 (p-value =
0.0858). None of the participants had more than 50,000 A. lumbricoides epg (high intensity per
WHO’s classification [8]) during the study (Fig 3b). The community prevalence of T. trichiura
Fig 2. Evolution of age profiles of CFA prevalence from 2014 to 2018.
https://doi.org/10.1371/journal.pntd.0008322.g002
Table 2. Evolution of circulating filarial antigenemia (FTS) scores in 320 individuals tested in 2014 and in 2018.
FTS score in June 2018
0 1 2 3 Total
FTS score in June 2014 0 224 0 0 0 224
1 23 1 1 0 25
2 20 4 0 0 24
3 16 18 13 0 47
Total 283 23 14 0 320
https://doi.org/10.1371/journal.pntd.0008322.t002
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infection was 4.1% in 2014 and 2.9% in 2018 (p-value = 0.2499). Arithmetic mean egg counts
were 8 epg in 2014, 10 epg in 2015, 31 epg in 2016, 28 in 2017 and 3 epg in 2018. All infections
detected in 2018 had egg counts lower than 1000 epg (Fig 3c).
Discussion
This study represents the longest and largest trial to date of semiannual community treat-
ment with ALB alone for LF elimination. Our results show that semiannual ALB was effective
for reducing LF prevalence in an area with moderately high endemicity in the Democratic
Republic of the Congo. MDA also greatly reduced STH prevalences and intensity in the
study area. Eight semiannual rounds of MDA with ALB decreased the CFA prevalence in the
study communities by 73% from 31.6% to 8.5% and decreased the Mf prevalence by 92.5%
from 12% to 0.9%. Of note, no child aged less than 10 years of age had a positive CFA test
result in 2018, and no person who was CFA-negative in 2014 was positive in 2018. Although
we have no data on CFA incidence rates prior to MDA, these results suggest that MDA dra-
matically reduced LF incidence in the study area. Results from this study were similar to
those obtained in a prior community study of semiannual ALB MDA that was conducted in
the Republic of the Congo, about 400 km from the current study site [5]. However, baseline
LF prevalences for CFA and mf in that area were only about half as high as those in the cur-
rent study. Taken together, these studies strongly support the provisional strategy for elimi-
nation of LF in Central Africa that was first issued by the WHO in 2012 and reaffirmed in
2017 [9]. They also suggest that LF transmission might be interrupted within a 5-year time
Table 3. Effect of semiannual mass administration of albendazole on soil-transmitted helminth infections.




Rounds of mass drug administration
before assessment
0 2 4 6 8
Hookworm
Number of positive samples 242 98 118 103 39




38.3 (33.0–43.9) 40.9 (34.9–
47.1)
21.2 (15.9–27.7) 63.8% < 0.0001




111 (66.7–155.3) 66.9 (45.6–
88.2)
31.0 (14.8–47.1) 93.2% < 0.0001










Number of positive samples 58 5 7 9 3
Prevalence (95% CI) 14.0 (11.0–
17.8)
2.3 (1.0–5.5) 2.3 (1.1–4.7) 3.6 (1.9–6.7) 1.6 (0.5–5.0) 88.6% < 0.0001




















Number of positive samples 17 5 11 12 5
Prevalence (95% CI) 4.1 (2.6–6.5) 2.3 (1.0–5.5) 3.6 (1.9–6.3) 4.8 (2.7–8.2) 2.7 (1.1–6.4) 34.0% 0.2011
Arithmetic mean eggs per g (95% CI) 8.0 (-0.8–17.0) 10.5 (-4.9–25.9) 31.3 (-11.7–74.3) 28.4 (-12.9–
69.6)
3.4 (0.2–6.6) 57.5% 0.2499
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Fig 3. Impact of semiannual treatments with albendazole on soil-transmitted helminth infections �epg: eggs per
gram.
https://doi.org/10.1371/journal.pntd.0008322.g003
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frame in LF endemic areas in Central Africa if programs can implement semiannual MDA
with ALB with high compliance.
The absence of SAEs in this study was welcome but not unexpected, given the known safety
record of ALB in LF elimination and STH control programs [10,11]. Although semiannual
MDA with ALB reduces mf prevalence more slowly than ivermectin plus albendazole during
the first year of intervention [12], it may be a safer regimen for LF elimination than IVM/ALB,
and that is particularly likely to be true in areas of Central Africa where LF is coendemic with
loiasis. However, a potential downside of MDA with ALB alone is that it may select for drug
resistance in nematode parasites if it is continued for many years [13].
A graph of treatment coverage over time revealed a saw-tooth pattern, with coverage oscil-
lating between 65% and 85% with lower values when the treatments were associated with the
annual parasitological assessments. The last round saw a significant drop in participation
(56%), possibly reflecting program fatigue on the part of some members of the community. If
community treatments have to be maintained for longer periods, one of the main challenges
will be to find ways to reinforce messages to improve and maintain compliance with MDA.
It is not surprising that community MDA with ALB had dramatic effects on hookworm
and ascariasis infections in the study communities [14,15]. It is also not surprising that semi-
annual ALB had only modest effects on Trichuris prevalence, because Trichuris is known to be
less susceptible to ALB than the other STH [14,15]. It is interesting to compare STH results
from this study to those reported from Seke Pembe in the Republic of the Congo [5]. Baseline
STH prevalences in this study differed significantly from those in Seke-Pembe: Hookworm
was the preponderant STH species in the present study (initial prevalence: 58.6%), followed by
A. lumbricoides (14%) and T. trichiura (4.1%), whereas corresponding baseline prevalences in
Seke-Pembe were 6.5%, 56.5% and 78.6%, respectively. In the latter site, two rounds of alben-
dazole led to the total disappearance of hookworm infection in the community. In the present
study site, the prevalence of hookworm infection was still slightly above 20% after 8 rounds of
community treatments. Reinfection with hookworm was certainly reduced, but it is still occur-
ring in Mbunkimi and Misay.
The prevalence of A. lumbricoides infection seemed to level off at a low value (2–3%) after a
dramatic reduction between the baseline year and year-1. Albendazole had little effect on T.
trichiura infection prevalence which was already low at baseline. Additional studies would be
needed to assess whether the small reservoirs of A. lumbricoides and T. trichiura are aggregated
within related individuals or locations in the study area. If that is the case, a different treatment
schedule or regimen might be employed to treat infected individuals and their family members
or to focus treatment for individuals who live in specific sectors. However, based on our
results, elimination of STH in the community is unlikely to be achieved using semiannual
albendazole alone.
This study has some limitations. First of all, for both logistical and ethical reasons, we chose
not to include a control community to monitor the level of W. bancrofti and STH infections
without intervention. Nonetheless, during the 4-year study, there were no significant changes
in the study communities, such as improvement of sanitary conditions or insecticide cam-
paigns, that may have impacted the transmission of LF and STH. Besides this, bednets that
were present in the households were not distributed as part of our trial. They were already
present in the village at the outset of the trial. We did not strictly assess their condition but for-
tuitous observations showed very degraded nets. In addition, although a prior study showed
that long-lasting insecticidal nets used during malaria programs can interrupt LF transmission,
that study also reported that Mf prevalence was not significantly affected during the 3-year
study [16]. Therefore, we firmly believe that the fast decrease in both CFA and Mf prevalence
is due to the effect of repeated treatments with albendazole.
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Finally, one factor to consider regarding STH results in 2018 is that the stools submitted
for examination were almost entirely provided by children. Therefore, according to what is
known about the age-profiles of the different STH species, STH prevalences in the community
may have been overestimated for Ascaris and Trichuris, but underestimated for hookworm. In
addition, persons in the study area who were noncompliant with MDA and not tested for STH
may also constitute an unmeasured reservoir of STH infection.
To conclude, our findings indicate that 4 years of semiannual community treatments with
albendazole alone with high treatment coverage decreased the Mf prevalence in the commu-
nity to less than 1%. In programmatic terms, this sentinel site has passed pre-TAS. However,
this is not sufficient to trigger a transmission assessment survey (TAS). TAS are conducted at
the scale of evaluation units. Although our study started in 2014, semiannual MDA with alben-
dazole started later in the rest of health area. Therefore, we would deferring TAS in this area
until all communities in the implementation unit have completed 4 years of semiannual MDA
with albendazole.
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